Lawsuits related to injuries and deaths linked to Xarelto continue to mount. If you believe you have a case regarding Xarelto, contact Saunders & Walker P.A. for a free case evaluation
Xarelto, the brand name for rivaroxaban, is a blood thinner manufactured by Bayer Health Group and marketed by the Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Marketed as an effective anti-coagulant alternative to Warfarin, Xarelto allegedly features less monitoring than Warfarin, making it a better choice for preventing deep vein thrombosis or pulmonary embolism and for treating atrial fibrillation.
Instead of providing the superior benefits, the drug resulted in thousands of product liability cases linked to injuries and deaths. Some study results also raise questions about the safety of Xarelto.
Some claimants contend that Janssen Pharmaceuticals failed to provide adequate warning about serious side effects of Xarelto, including severe uncontrollable bleeding, which potentially leads to bleeding out and death. Some claims involve liver damage and liver failure.
In October 2012, the Institute for Safe Medicine Practices (ISMP) published its QuarterWatch results for first quarter 2012. ISMP explains that QuarterWatch is a surveillance program monitoring serious, disabling and fatal adverse drug events (ADEs). Q1 results showed 356 adverse drug effects for which Xarelto was the primary drug suspected in the ADEs. The largest category of events reported involved pulmonary embolisms, one of the very conditions the drug is marketed to prevent.
In November 2012, Physicians Weekly revealed that the FDA expanded the use of Xarelto, despite incidents of serious adverse effects, including reported deaths.
By 2015, reports were already available indicating that some of the very people on the treatment guideline panels touting expansion of the use of the drug also had financial ties to the pharmaceutical industry. MedPage Today/Journal Sentinel reported that several doctors served as paid speakers and consultants for companies making Xarelto. After these physicians recommended expanding the use of Xarelto, the number of patients prescribed Xarelto increased significantly.
Cases linked to Xarelto continue to mount, with Chicago Tribune indicating that thousands of lawsuits accuse Johnson & Johnson and Janssen of concealing knowledge about risks of taking Xarelto from physicians and the public.
Product liability cases provide patients, consumers, and clients the ability to fight back against manufacturers and others involved in failing to warn, improper labeling and negligence in manufacturing and marketing products, including Xarelto.
If you or your loved one experienced abnormal bleeding, gastrointestinal bleeding, brain hemorrhage, liver damage, other side effects or death that you believe is linked to Xarelto, contact Saunders & Walker P.A. We have the expertise to determine if you likely have a product liability case and to represent you in your Xarelto lawsuit.